4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (17.39) | 18.7374 |
1990's | 4 (17.39) | 18.2507 |
2000's | 5 (21.74) | 29.6817 |
2010's | 9 (39.13) | 24.3611 |
2020's | 1 (4.35) | 2.80 |
Authors | Studies |
---|---|
Abell, CW; Brossi, A; Gessner, W; Shen, R | 1 |
Good, AC; Peterson, SJ; Richards, WG | 1 |
Castagnoli, N; Mabic, S | 1 |
Sullivan, JP; Tipton, KF | 1 |
Hansen, S; Jones, K; Perry, TL; Wall, RA | 1 |
Cavalla, D; Hadjiconstantinou, M; Laird, HE; Neff, NH | 1 |
Abell, CW; Brossi, A; Gessner, W; Shen, RS | 1 |
Iwasaki, K; Naritomi, Y; Niwa, T; Noda, K; Shiraga, T | 1 |
Hattori, K; Ishida, J; Iwashita, A; Matsuoka, N; Mihara, K; Yamamoto, H | 1 |
Cano, J; Hernández-Romero, MC; Machado, A; Santiago, M | 1 |
Dodd, CA; Klein, BG | 1 |
Ansah, TA; Bubser, M; Deutch, AY; Ferguson, MC; Montine, TJ; Nayyar, T; Neely, MD; Shawn Goodwin, J | 1 |
Fujita, K; Katafuchi, T; Kido, MA; Nakabeppu, Y; Noda, M; Ohno, M; Sakumi, K; Seike, T; Takaki, A; Tanaka, Y; Yamada, H; Yamaguchi, H; Yamakawa, Y; Yutsudo, N | 1 |
Cho, KH; Cho, SH; Hong, J; Ju, MS; Kim, DH; Kim, HG; Kim, SY; Lee, EH; Oh, MS; Park, W | 1 |
Cho, KH; Doo, AR; Eun-Kyung, K; Hong, J; Jung, JH; Jung, WS; Kim, SN; Lee, H; Moon, SK; Park, HJ; Park, JY | 1 |
Choi, JG; Huh, Y; Kim, HG; Kim, MC; Kim, SY; Oh, MS; Yang, WM | 1 |
Charlton, C; King, JM; Mackey, V; Muthian, G; Smith, M | 1 |
Bai, J; Jia, JJ; Kwon, Y; Wang, SD; Zeng, XS | 1 |
Inoue, T; Murayama, N; Sasaki, E; Shimizu, M; Uehara, S; Uno, Y; Yamazaki, H | 1 |
Bai, Q; Gao, J; Jia, Y; Jiang, R; Lai, F; Liu, X; Tang, Y; Xiao, H; Xie, W | 1 |
Goshima, Y; Hasegawa, M; Hensley, K; Masukawa, D; Nagai, J; Ohshima, T; Togashi, K; Tonouchi, A | 1 |
Agúndez, L; Antunes, AS; Bardelli, M; Bezard, E; Björklund, A; Björklund, T; Dovero, S; Henckaerts, E; Li, Q; Linden, RM; Pioli, EY; Rosenblad, C | 1 |
Cui, X; He, Z; Hu, L; Hua, L; Li, M; Liu, J; Yan, J | 1 |
23 other study(ies) available for 4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Article | Year |
---|---|
Synthesis and dihydropteridine reductase inhibitory effects of potential metabolites of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dihydropteridine Reductase; Humans; Hydroxylation; NADH, NADPH Oxidoreductases; Pyridines; Structure-Activity Relationship | 1985 |
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
Topics: Carbolines; Chemical Phenomena; Chemistry, Physical; Electrochemistry; Imidazoles; Indoles; Molecular Structure; Pyridines; Structure-Activity Relationship | 1993 |
Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Cattle; Dopamine Agents; Kinetics; Liver; Molecular Structure; Monoamine Oxidase; Oxidation-Reduction; Structure-Activity Relationship; Substrate Specificity | 1996 |
Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cattle; Dihydropyridines; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction | 1992 |
4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Carbolines; Corpus Striatum; Dopamine; Isoquinolines; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Pyridines; Substantia Nigra; Tetrahydroisoquinolines | 1987 |
Intracerebroventricular administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite 1-methyl-4-phenylpyridinium ion (MPP+) decrease dopamine and increase acetylcholine in the mouse neostriatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Animals; Caudate Nucleus; Choline; Dopamine; Injections, Intraventricular; Male; Mice; Putamen; Pyridines | 1985 |
Inhibition of dihydropteridine reductase by novel 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydropteridine Reductase; Humans; Hydroxylation; Liver; NAD; NADH, NADPH Oxidoreductases; Pyridines; Rats; Structure-Activity Relationship; Synaptosomes | 1984 |
Isolation and characterization of an alicyclic amine N-sulfotransferase from female rat liver.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Chromatography, DEAE-Cellulose; Cytosol; Electrophoresis, Polyacrylamide Gel; Female; Immunoblotting; Immunochemistry; In Vitro Techniques; Liver; Male; Molecular Sequence Data; Rats; Rats, Sprague-Dawley; Sex Characteristics; Sulfotransferases | 1994 |
4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antipyrine; Benzamides; Humans; Inhibitory Concentration 50; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship | 2005 |
Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Lipopolysaccharides; Male; Microdialysis; Nerve Endings; Neuroprotective Agents; Parkinson Disease; Perfusion; Rats; Rats, Wistar; Simvastatin | 2009 |
Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: an immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatu
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorpyrifos; Disease Models, Animal; Drug Combinations; Drug Interactions; Glial Fibrillary Acidic Protein; Insecticides; Mice; Mice, Inbred C57BL; Neostriatum; Neuropil; Parkinsonian Disorders; Permethrin; Tyrosine 3-Monooxygenase | 2009 |
Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Cell Count; Cerebral Cortex; Denervation; Dopamine; Humans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Norepinephrine; Parkinsonian Disorders; Serotonin | 2009 |
Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Hydrogen; Lipid Peroxidation; Mice; Neurodegenerative Diseases; Neurons; Oxidative Stress; Oxygen; Parkinson Disease; Risk; Water; Water Supply | 2009 |
Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Caspase 3; Cell Death; Cells, Cultured; Disease Models, Animal; Dopamine; Drugs, Chinese Herbal; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mitochondria; Neurons; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Substantia Nigra | 2010 |
Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caspase 3; Cell Line, Tumor; Chromones; Cytotoxins; Disease Models, Animal; Dopamine; Drugs, Chinese Herbal; Enzyme Inhibitors; Humans; Magnoliopsida; Male; Mice; Mice, Inbred C57BL; Morpholines; Motor Activity; Neuroblastoma; Neurons; Neuroprotective Agents; Parkinson Disease; Phosphorylation; Phytotherapy; Proto-Oncogene Proteins c-akt | 2010 |
Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Caspase 3; Cell Death; Disease Models, Animal; Dopamine; Male; Medicine, Korean Traditional; Mice; Mice, Inbred C57BL; Neurons; Nitric Oxide; Oxidopamine; Parkinson Disease; PC12 Cells; Phytotherapy; Plant Extracts; Plant Roots; Polygala; Rats; Reactive Oxygen Species | 2011 |
L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Female; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 2011 |
The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caspase 12; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Gene Expression Regulation; Heat-Shock Proteins; MAP Kinase Kinase 4; Mice; Mice, Transgenic; MPTP Poisoning; PC12 Cells; Protein Serine-Threonine Kinases; Rats; Signal Transduction; Thioredoxins; TNF Receptor-Associated Factor 2; Transcription Factor CHOP | 2014 |
Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Callithrix; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dinitrocresols; Female; Hydroxylation; Inactivation, Metabolic; Liver; Male; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Oxygenases | 2015 |
Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Enteric Nervous System; Gastrointestinal Diseases; Gastrointestinal Microbiome; Inflammation; Male; Mice, Inbred C57BL; Parkinson Disease | 2018 |
Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; Intercellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Motor Activity; Neostriatum; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Phosphorylation; Substantia Nigra; Suppression, Genetic | 2019 |
Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dependovirus; Drug Evaluation, Preclinical; Female; Genes, Reporter; Genes, Synthetic; Genetic Vectors; GTP Cyclohydrolase; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Proof of Concept Study; Putamen; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Tyrosine 3-Monooxygenase | 2019 |
MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease by regulating inducible nitric-oxide synthase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Humans; Insulin-Like Growth Factor I; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neuroprotective Agents; Nitric Oxide Synthase Type II; Parkinson Disease, Secondary | 2020 |